Daniel R van Langenberg1, Greg W Yelland2,3, Stephen R Robinson3, Peter R Gibson1,2. 1. Eastern Health Clinical School, Monash University & Department of Gastroenterology & Hepatology, Eastern Health, Box Hill, Victoria, Australia. 2. Central Clinical School, Monash University & Department of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia. 3. School of Health Sciences, RMIT University, Bundoora, Victoria, Australia.
Abstract
BACKGROUND: Patients with Crohn's disease (CD) frequently complain of cognitive difficulties such as problems with concentration and clouding of thought, yet this has scarcely been objectively defined and underlying mechanisms remain unknown. OBJECTIVE: The objective of this article is to objectively measure cognitive impairments in patients with CD compared with healthy controls, and if present, to identify potentially modifiable, contributing factors associated with cognitive impairment. METHODS: CD patients and healthy age-/sex-matched controls completed surveys encompassing clinical, demographic, psychiatric, fatigue and sleep parameters. Contemporaneously, disease activity assessment with serum CRP, faecal calprotectin, Harvey-Bradshaw Index and the Subtle Cognitive Impairment test (SCIT) were performed, with the primary measure of response time (SCIT-RT) compared between groups. Multiple linear regression assessed for factors associated with slower SCIT-RT, denoting subtle cognitive impairment. RESULTS: A total of 49 CD and 31 control individuals participated, with median age 44 years (range 22-65) and 43 years (21-63), respectively. Compared to controls, SCIT-RT was slower across all timepoints in CD patients (ANOVA p < 0.001). In multivariate analysis, serum CRP (standardised beta coefficient 0.27, 95% CI (0.02, 0.51)), abdominal pain (0.43 (0.16, 0.70)), plasma haemoglobin (1.55 (1.42, 1.68)), and concurrent fatigue (0.56 (0.25, 0.88)) were each independently associated with slower SCIT-RT in CD (each p < 0.05), with a trend for poorer sleep quality 0.54 (-0.03, 1.11) (p = 0.06), yet conversely, higher faecal calprotectin titres were associated with faster SCIT-RT (-1.77 (-1.79, -1.76), p < 0.01). CONCLUSIONS: Patients with CD demonstrated subtle cognitive impairment utilising the objective SCIT, correlating with systemic inflammation and other disease burden measures, although higher faecal calprotectin titres were unexpectedly associated with less cognitive impairment.
BACKGROUND:Patients with Crohn's disease (CD) frequently complain of cognitive difficulties such as problems with concentration and clouding of thought, yet this has scarcely been objectively defined and underlying mechanisms remain unknown. OBJECTIVE: The objective of this article is to objectively measure cognitive impairments in patients with CD compared with healthy controls, and if present, to identify potentially modifiable, contributing factors associated with cognitive impairment. METHODS:CDpatients and healthy age-/sex-matched controls completed surveys encompassing clinical, demographic, psychiatric, fatigue and sleep parameters. Contemporaneously, disease activity assessment with serum CRP, faecal calprotectin, Harvey-Bradshaw Index and the Subtle Cognitive Impairment test (SCIT) were performed, with the primary measure of response time (SCIT-RT) compared between groups. Multiple linear regression assessed for factors associated with slower SCIT-RT, denoting subtle cognitive impairment. RESULTS: A total of 49 CD and 31 control individuals participated, with median age 44 years (range 22-65) and 43 years (21-63), respectively. Compared to controls, SCIT-RT was slower across all timepoints in CDpatients (ANOVA p < 0.001). In multivariate analysis, serum CRP (standardised beta coefficient 0.27, 95% CI (0.02, 0.51)), abdominal pain (0.43 (0.16, 0.70)), plasma haemoglobin (1.55 (1.42, 1.68)), and concurrent fatigue (0.56 (0.25, 0.88)) were each independently associated with slower SCIT-RT in CD (each p < 0.05), with a trend for poorer sleep quality 0.54 (-0.03, 1.11) (p = 0.06), yet conversely, higher faecal calprotectin titres were associated with faster SCIT-RT (-1.77 (-1.79, -1.76), p < 0.01). CONCLUSIONS:Patients with CD demonstrated subtle cognitive impairment utilising the objective SCIT, correlating with systemic inflammation and other disease burden measures, although higher faecal calprotectin titres were unexpectedly associated with less cognitive impairment.
Authors: B Gwen Windham; Brittany N Simpson; Seth Lirette; John Bridges; Lawrence Bielak; Patricia A Peyser; Iftikhar Kullo; Stephen Turner; Michael E Griswold; Thomas H Mosley Journal: J Am Geriatr Soc Date: 2014-12 Impact factor: 5.562
Authors: D R van Langenberg; P Della Gatta; S A Warmington; D J Kidgell; P R Gibson; A P Russell Journal: J Crohns Colitis Date: 2013-08-12 Impact factor: 9.071
Authors: Raj C Shah; Robert S Wilson; Yuxiao Tang; Xinqi Dong; Anne Murray; David A Bennett Journal: Neuroepidemiology Date: 2008-11-12 Impact factor: 3.282
Authors: Sarah E Barnes; Kristy A Zera; Geoffrey T Ivison; Marion S Buckwalter; Edgar G Engleman Journal: J Neuroinflammation Date: 2021-09-12 Impact factor: 8.322
Authors: Sarah Talley; Rasa Valiauga; Lillian Anderson; Abigail R Cannon; Mashkoor A Choudhry; Edward M Campbell Journal: J Neuroinflammation Date: 2021-11-10 Impact factor: 8.322
Authors: Ruth Ann Marrie; Lesley Graff; John R Walker; John D Fisk; Scott B Patten; Carol A Hitchon; Lisa M Lix; James Bolton; Jitender Sareen; Alan Katz; Lindsay I Berrigan; James J Marriott; Alexander Singer; Renée El-Gabalawy; Christine A Peschken; Ryan Zarychanski; Charles N Bernstein Journal: JMIR Res Protoc Date: 2018-01-17